March 10, 2026
Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board
January 21, 2026
Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel
November 11, 2025
Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Nonclinical Development
October 9, 2025
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to its Board of Directors
September 10, 2025
Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
